How has been the historical performance of the Norris Medicines?

Answer:The historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years, with significant losses reported. Breakdown: Norris Medicines has experienced a downward trajectory in net sales, decreasing from Rs 16.27 crore in March 2019 to Rs 5.82 crore in March 2025. The total operating income followed a similar pattern, dropping from Rs 16.27 crore in March 2019 to Rs 5.82 crore in March 2025. The company's total expenditure, excluding depreciation, also decreased from Rs 16.88 crore in March 2019 to Rs 6.08 crore in March 2025. Despite this reduction in costs, the operating profit (PBDIT) has remained negative since March 2021, with a loss of Rs 0.20 crore in March 2025. Profit before tax has also been negative, with a loss of Rs 1.18 crore in March 2025, while profit after tax showed a loss of Rs 1.24 crore for the same period. The company's reserves have been negative since March 2020, reaching Rs -24.79 crore in March 2025. The book value per share has also deteriorated, standing at Rs -13.73 in March 2024. Overall, Norris Medicines has faced significant challenges, reflected in its declining sales, persistent losses, and negative equity.